1 SARS-CoV-2 antibody response among COVID-19 patients is not affected by 2 parasite co-infection

- 3 Teklay Gebrecherkos¹, Yazezew Kebede Kiros¹, Feyissa Challa², Atsbeha Gebreegzabher², Saro
- 4 Abdella², Dereje Leta², Abraham Desta³, Ataklti Hailu³, Geremew Tasew², Mahmud Abdulkader¹,
- 5 Masresha Tessema², Getachew Tollera², Zekarias Gessesse Arefaine¹, Henk HDF Schallig⁴, Britta
- 6 C. Urban⁵, Tobias F. Rinke de Wit^{6,7}, Dawit Wolday^{1,2}
- 7 Running title: Antibody response in parasite co-infected SARS-CoV-2 patients
- 8 ¹Mekelle University College of Health Sciences, Mekelle, Ethiopia
- 9 ²Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- 10 ³Tigray Health Research Institute, Mekelle, Ethiopia
- ⁴Department of Medical Microbiology, and Infection Prevention, Experimental Parasitology Unit,
- 12 Amsterdam Institute for Infection and Immunity, Academic Medical Center at the University of
- 13 Amsterdam, Amsterdam, The Netherlands
- 14 ⁵Liverpool School of Tropical Medicine
- ⁶Amsterdam Institute Global Health and Development, Academic Medical Center, University of
- 16 Amsterdam, Amsterdam, The Netherlands
- ¹⁷ ⁷Joep Lange Institute, Amsterdam, The Netherlands.
- 18
- 19 ***Correspondence**: Teklay Gebrecherkos. Department of Medical Microbiology and Immunology, CHS,
- 20 MU, Ethiopia. Email: estiftg17@gmail.com
- 21
- 22
- 23
- 23
- 24
- 25
- 26
- _
- 27
- 28
- 29

30 Abstract

Background: B-cell hypo-responsiveness has been associated with intestinal parasitic coinfection. The effect of parasite co-infection on antibody response to SARS-CoV-2 is unknown. Here, we aimed to determine antibody response to SARS-CoV-2 among COVID-19 patients coinfected with intestinal parasites and those without parasite co-infection.

Methods: In this prospective cohort study, a total of 589 samples were serially collected from 72 RT-PCR-confirmed patients. Anti-SARS-CoV-2 nucleocapsid protein (NP) antibody titers were measured longitudinally during hospitalization. SARS-CoV-2 infection was confirmed by RT-PCR on samples obtained from nasopharyngeal swabs, while direct microscopic examination, modified Ritchie concentration, and Kato-Katz methods were used to identify parasites and ova from fresh stool samples. Data were analyzed using STATA version 14.

Results: Of the 72 COVID-19 patients, 39 (54.2%) were co-infected with intestinal parasites while 41 33 (45.8%) had no parasitic co-infection. Overall, the median cut-off index (COI) for anti-NP 42 antibody titer among COVID-19 patients co-infected with parasites was 6.91 (IQR: 0.55-40.7) 43 compared to 7.51 (IQR: 0.21-59.21) in those without parasites (p=0.764). In addition, 174/261 44 45 [66.7% (95% CI: 60.68-72.16)] and 231/328 [70.4% (95% CI: 65.23-75.14)] specimens from COVID-46 19 patients with parasite co-infection and without parasites, respectively, had anti-SARS-CoV-2 antibody above the cut-off COI value (p=0.328). The positivity rate for anti-SARS-CoV-2 NP < 14 47 days after symptom onset was 66.3% (95% CI: 60.21-71.85) and 70.0% (95% CI: 64.72-74.74) for 48 those not infected and co-infected with parasites, respectively (p=0.343). In addition, 31/7249 (41.9%) of the patients who were negative at the time of enrollment were seroconverted. The 50 trend in anti-NP antibodies among seroconverted individuals with and without parasites is also 51 similar. 52

Conclusions: Co-infection with parasitic infection has very little effect on the anti-SARS-CoV-2
 antibody immune response. Further studies on the profile of neutralizing antibodies in parasite endemic areas are warranted to ascertain vaccine efficacy.

56 Keywords: COVID-19, SARS-CoV-2, antibody, Ig, anti-NP antibody, parasite, helminth, protozoa

57 Author's summary

Pre-existing co-infection with intestinal parasites has been shown to diminish antibody response 58 to a multitude of heterologous pathogens or vaccines. However, the effect of parasite co-59 60 infection on antibody response to SARS-CoV-2 is unknown. We determined the anti-nucleocapsid 61 protein (NP) antibody response to SARS-CoV-2 among COVID-19 patients co-infected with intestinal parasites and compared their response to those without parasites. There was no 62 difference in anti-NP positivity rate, seroconversion, or titer level among COVID-19 patients with 63 or without parasitic co-infection. Further studies on the profile of neutralizing antibodies in 64 parasite-endemic areas are warranted to ascertain vaccine efficacy. 65

66 Introduction

67 Antibody testing for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is used for 68 epidemiological surveillance, in aiding the diagnosis of (previous) coronavirus disease 2019 69 (COVID-19), and in the assessment of herd immunity following natural infection or after vaccine administration [1-9]. Several reports have demonstrated a lack of specificity for SARS-CoV-2 70 71 antibodies in evaluations of samples both pre-pandemic as well as samples collected during the 72 COVID-19 pandemic period [10-18]. Such samples derived from parasite-endemic areas may cross-react to some of the SARS-CoV-2 antigenic epitopes [19, 20]. On the other hand, antibody 73 74 response, including neutralizing antibody titers may be influenced in individuals with profound 75 immune suppression, such as HIV-1 [21], though others have not demonstrated such effects [22, 76 23].

B-cell hypo-responsiveness is associated with intestinal parasite co-infection in endemic areas
[24]. Indeed, pre-existing co-infection with parasites has been shown to diminish antibody
response to influenza, hepatitis B, pneumococcal, cholera, tetanus, and malarial vaccines [2531].

Nonetheless, the effect of parasite co-infection on antibody response to SARS-CoV-2 among COVID-19 patients remains to be elucidated. In addition, seroconversion might also be reduced or delayed in SARS-CoV-2-infected patients with pre-existing parasite co-infection. Here, we

determined whether pre-existing co-infection with parasites impacts SARS-CoV-2 antibody
 responses and seroconversion.

86 Materials and Methods

87 Study design, period, and setting

The study is part of the ongoing Profile-Cov study, a prospective observational cohort study in Ethiopia with rapid diagnostic profiling of SARS-CoV-2 in the context of persistent immune activation (Clinicaltrials.gov: NCT04473365). Consecutive patients with confirmed Real–Time polymerase chain reaction (RT-PCR) test results were enrolled. They were recruited from Mekelle University College of Health Sciences (Kuyha COVID-19 Isolation and Treatment Center), Mekelle City, Northern Ethiopia, prospectively between July 15 and October 28, 2020.

94 Individuals presenting to the Isolation and Treatment Center were screened for SARS-CoV-2 infection with a nasopharyngeal swab and an RT-PCR confirmed patients. Following the 95 96 declaration by the WHO that COVID-19 has become a pandemic, the Ethiopian Ministry of Health 97 implemented a mass screening of all travelers, people who had come in contact with COVID-19 patients, those from high-risk settings (e.g. healthcare workers), as well as those with symptoms 98 and signs suggestive of SARS-CoV-2 infection [32]. All cases with a confirmed SARS-CoV-2 99 100 infection were admitted to dedicated COVID-19 Isolation and Treatment Centers. Patients were 101 admitted irrespective of clinical severity status. Whenever patients progress to severe or critical 102 COVID-19, they were admitted to the intensive care unit (ICU). None of the patients received 103 SARS-CoV-2 vaccination as they were enrolled before the introduction of a vaccine to the country.

104 Data and specimen collection

Sociodemographic, clinical data, and laboratory data were collected using standardized Case
 Record Forms (CRFs) adapted from the International Severe Acute Respiratory and Emerging
 Infection Consortium's (ISARIC) CRFs for emerging severe acute respiratory infections [33]. All
 data were then entered onto electronic medical records.

109 For analysis of anti-NP antibody kinetics, samples were drawn serially from 72 SARS-CoV-2 110 RT-PCR-confirmed patients. Overall, patients were followed for a median of 31 [interquartile range (IQR): 17-32] days, and ranging between 7 to 37 days. Whenever possible, samples were drawn every 3 days during follow-up. Thus, multiple samples were drawn per individual at a given time interval (0–3, 4–6, 7–9, 10–12, 13–15, 16–18, 19–21, 22–24, 25–27, 28–30, 31–33, 34–36, 37–39, and \geq 40 days after onset of symptoms). Notably, only one sample per time interval was included from a single participant. Specimens were immediately transported to the Central Laboratory of the university hospital, and separated plasma was frozen at –80°C until further analysis.

118 Laboratory assays

SARS-CoV-2 infection was confirmed by RT-PCR on samples obtained from nasopharyngeal 119 swabs, as described previously [32]. The antibody profile in this study was determined using the 120 121 Roche Elecsys electrochemiluminescent immunoassay (ECLIA) that targets the nucleocapsid 122 protein (NP). Testing, including the cut-off index (COI) for anti-NP total immunoglobulin (Ig) titer was done following the manufacturer's instructions, as described previously [34]. Seroconversion was 123 ascertained if a patient with a negative antibody test at the time of enrollment becomes positive 124 with the assays tested during follow-up. For estimating the day of seroconversion, the day's post-125 symptom onset was determined for symptomatic cases. For asymptomatic patients, we added 6 126 days (median time between symptom onset and date of positive PCR testing among symptomatic 127 cases) to the PCR testing date. Fresh stool sample specimens were also obtained for examination 128 129 for parasites and ova. The analysis included direct microscopic examination, modified Ritchie concentration method, and Kato-Katz method, as described previously [35]. 130

131 Statistical Analysis

Baseline characteristics for continuous variables were expressed as the median with IQR, and for categorical variables as proportions. Categorical variables were compared using Fisher's exact test or χ^2 test, and continuous variables were compared by Mann–Whitney U or Kruskal–Wallis tests as appropriate. The primary outcomes for this study were anti-NP total Ig positivity rate or titers above the COI value, according to sampling time (days after symptom onset). The positivity rate was presented as proportion and 95% confidence interval (CI) limits. Data were analyzed using STATA (Statistical package v. 14.0, StataCorp, Texas, USA).

139 Ethical considerations

Participants provided written informed consent to participate in the Profile-Cov study. The study protocol was reviewed and approved by the Health Research Ethics Review Committee (HRERC) of Mekelle University College of Health Sciences (#ERC 1769/2020). Written informed consent was obtained from all study participants. However, specimens used as controls from pre– pandemic period were specimens from biobank and individual study participant consent was not obtained. Nonetheless, all personal identifiers were–linked from the sources, and the HRERC has reviewed and approved it.

147

148 **Results**

149 General characteristics

150 Detailed demographic and clinical characteristics of the cohort have been described previously in detail in our published articles [34, 35]. For this sub-study, 72 PCR-confirmed COVID-19 151 patients were enrolled and contributed a total of 589 samples [median of 9 (IQR: 5 - 11) paired 152 153 samples per patient] collected serially over time. Of the 72 COVID-19 patients, 39 (54.2%) were co-infected with intestinal parasites while 33 (45.8%) had no parasitic co-infection. Details in 154 sociodemographic characteristics and prevalence of parasite co-infection are summarized in 155 **Table 1**. Frequent symptoms were fever, dyspnoea, cough, and headache. Except for dyspnoea 156 which was significantly higher among those without parasites, clinical symptoms were similar in 157 both groups. In addition, the groups did not differ by age, sex, comorbidities, or severity. 158

159 Longitudinal SARS-CoV-2 antibody response

The overall antibody NP total Ig response is summarized in **Table 2**. A total of 589 specimens derived at different time points were evaluated. The overall positivity rate for anti-SARS-CoV-2 NP total Ig was 68.8% (95% CI: 65.01-72.51); 70.4% (95% CI: 65.46-75.39) for those infected with parasites and 66.7% (95% CI: 60.91-72.42) for those not co-infected with parasites (p=0.328). Additionally, the positivity rate was 69.7% (95% CI: 62.61-76.78) for those infected with helminths and 68.4% (95% CI: 63.95-72.84) for those not co-infected with helminths (p=0.760).

Whereas the anti-SARS-CoV-2 NP total Ig was 68.8% (95% CI: 65.01-72.51) among those infected
with protozoa, it was 67.4% (95% CI: 62.62-72.13) among those without protozoa (p=0.333).
Moreover, we did not observe differences in the anti-NP total Ig titers between those infected
with parasites and those without parasite co-infection (Table 2).

170 The kinetics of the anti-NP total Ig response are shown in Figure 1. The seropositivity rate was 171 low at the time of enrollment in the study. Overall the positivity rate for anti-NP total Ig was 172 11.1% in those co-infected with parasites and 14.3% in those without parasites (Figure 1A). Similar trends were observed among those with or without helminth (Figure 1B), or with or 173 174 without protozoa (Figure 1C). However, during the first 15 days after the onset of symptoms, the 175 positivity rate increased significantly reaching above 50% positivity rate, irrespective of parasite 176 co-infection status. During the period 2- to 3 weeks after the onset of symptoms, the positivity rate of all the assays was increased, ranging between 67.3% and 81.3%. Between 3 and 6 weeks 177 178 after the onset of symptoms, the positivity rate continued to increase for all the assays, ranging 179 from 84.6% to 90.9%. Positive anti-NP total Ig titer was detectable (i.e. $COI \ge 1.0$) as early as 7 to 180 12 days after onset of symptoms for all patients (Figure 1D-F). Because of the small sample size, 181 we did not determine trends stratified by severity status.

182 Seroconversion of SARS-CoV-2 antibodies

183 Patients who were antibody-negative at the time of enrollment in the study, but who became 184 antibody-positive during follow-up were considered seroconverters. Overall, a total of 31 185 (41.9%) were seroconverted. A total of 256 sample pairs were evaluated. Seroconversion trends 186 are shown in Figure 2. Patients started to seroconvert as early as 4 to 9 days after the onset of 187 symptoms, reaching around 25%. The rate of seroconversion within the first 15 days after the onset of symptoms increased to 44.4%. During the same period, the rate of seroconversion for 188 189 those with parasites was 47.1% (95% CI: 20.61-76.94), and for those without parasitic coinfection was 40.0% (95% CI: 3.06-76.94), and the difference was not statistically significant 190 (p=0.722). In addition, the seroconversion rate increased further during 2- to 3 weeks after the 191 192 onset of symptoms, ranging between 61.5% and 68.0%, respectively. The seroconversion rate 193 continued to increase reaching 100% after \geq 39 days of symptom onset in all groups (Figure 2A).

Trends in anti-NP total Ig titers were also similar in patients irrespective of the presence of parasite co-infection or not (**Figure 2B**). Whereas the median seroconversion time for those with parasites was 13 (IQR: 7-21) days, it was 15 (IQR: 10-16) days for those without parasitic coinfection (p=927). Overall, there was no difference in seroconversion trend between those who were co-infected with parasites and those without parasites. Due to the small sample size, however, we did not do an analysis stratified by helminths and protozoa.

200 Discussion

In this study, we determined antibody responses among SARS-CoV-2 patients co-infected with parasites. To the best of our knowledge, this report is the first to determine the longitudinal SARS-CoV-2 antibody response in COVID-19 patients also co-infected with intestinal parasites. SARS-CoV-2 patients with parasite co-infection did not exhibit different profiles in antibody response or seroconversion patterns.

206 Several reports have previously documented that parasites downregulate antibody responses to 207 heterologous pathogen and vaccine responses [25-31]. Likewise, we expected an impaired antibody response to SARS-CoV-2 among COVID-19 patients co-infected with parasites [24]. 208 209 Given the presence of a high level of cross-reactivity between SARS-CoV-2 and parasites [10-20], 210 the expected reduction in antibody response might have been compensated by the presence of cross-reacting antibodies also in patients with COVID-19. Furthermore, it has been demonstrated 211 that a reduced frequency of SARS-CoV-2-reactive CD4+ T helper cells without an effect on the 212 213 expression of SARS-CoV-2-reactive CD8+ T cells [36]. Thus, it is plausible to postulate that parasite-induced reduced CD4+ T helper cells do not affect anti-NP antibody responses to SARS-214 215 CoV-2.

The strength of the current study is the use of longitudinal samples derived from the same patient. However, limitations include smaller sample sizes and a lack of determination of neutralizing antibody titers. In addition, anti-NP antibody response has not been stratified by severity status, though in our set-up we did not find differences in antibody profile by severity status [34]. The impact of parasite co-infection on the efficacy of SARS-CoV-2 vaccines in endemic areas is unknown [37]. Unraveling the differential antibody response profile between individuals with the parasite and those without parasite co-infection may have implications in the development and interpretation of diagnostic tools as well as the monitoring of vaccines in parasite-endemic areas. Further studies are needed to investigate the effects of co-infection with parasites on the efficacy and durability of antibody responses to SARS-CoV-2 vaccines.

Informed Consent Statement: Written informed consent was obtained from all study
 participants. All personal identifiers were de–linked from the sources.

Acknowledgments: The investigators thank EDCTP for providing funding to the project, COVID-19 patients and all individuals who provided specimens for control, and the medical staff who provided care of the patients.

232

233 **References**

Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.
 Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383:1724 -1734.

236 2. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.

Prevalence of SARS -CoV -2 in Spain (ENE -COVID): a nationwide, population-based
 seroepidemiological study. Lancet 2020; 396:535-544.

Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al. Humoral
 response and PCR positivity in patients with COVID -19 in the New York City region, USA: an
 observational study. Lancet Microbe 2020; 1: e283-e289.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2
 in patients with COVID-19. Nat Med 2020; 26:845-848.

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe acute
 respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019
 patients. Emerg Infect Dis 2020; 26: 1478–1488.

247 6. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in
248 patients of novel coronavirus disease 2019. Clin Infect Dis 2020; 71: 2027-2034.

Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. Different longitudinal patterns of nucleic
 acid and serology testing results based on disease severity of COVID-19 patients. Emerg
 Microbes Infect. 2020: 9: 833-836.

- Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
 Differences in antibody kinetics and functionality between severe and mild severe acute
 respiratory syndrome coronavirus 2 infections. J Infect Dis 2020; 222:1265-1269.
- Margolin E, Burgers WA, Sturrock ED, Mendelson M, Chapman R, Douglass N, et al. Prospects
 for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. Nat Rev Microbiol 2020; 18:
 690-704.
- 10. Steinhardt LC, Ige F, Iriemenam NC, Greby SM, Hamada Y, Uwandu M, et al. Cross-reactivity
 of two SARS-CoV-2 serological assays in a setting where malaria is endemic. J Clin Microbiol
 2021; 59: e0051421. doi:10.1128/JCM.00514-21
- 11. Vanroye F, Bossche DVD, Brosius I, Tack B, Esbroeck MV, Jacobs J. COVID-19 antibody
 detecting rapid diagnostic tests show high cross-reactivity when challenged with pre pandemic malaria, schistosomiasis and dengue samples. Diagnostics (Basel). 2021; 11: 1163.
 doi:10.3390/diagnostics11071163
- 12. Mveang Nzoghe A, Essone PN, Leboueny M, Maloupazoa Siawaya AC, Bongho EC, Mvoundza
 Ndjindji O, et al. Evidence and implications of pre-existing humoral cross-reactive immunity
 to SARS-CoV-2. Immun Inflamm Dis 2021; 9: 128-133. doi:10.1002/iid3.367
- 13. Baker OR, Grabowski MK, Galiwango RM, Nalumansi A, Serwanga J, Clarke W, et al.
 Differential performance of CoronaCHEK SARS-CoV-2 lateral flow antibody assay by
 geographic origin of samples. J Microbiol 2021; doi:10.1101/2021.04.12.21255284
- 14. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of preexisting serological cross-reactivity against severe acute respiratory syndrome coronavirus-2
 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis 2021; 102: 577-583.
 doi:10.1016/j.ijid.2020.10.104

- 275 15. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited
- specificity of serologic tests for SARS-CoV-2 antibody detection, Benin. Emerg Infect Dis 2021;

277 27: 233–237. doi:10.3201/eid2701.203281

- 16. Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al. Limited
 specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African
 origin. Trop Med Int Health 2021; 26: 621-631. doi:10.1111/tmi.13569
- 17. Woodford J, Sagara I, Dicko A, Zeguime A, Doucoure M, Kwan J, et al. SARS-CoV-2 seroassay
 optimization and performance in a population with high background reactivity in Mali. J Infect
 Dis 2021; doi:10.1093/infdis/jiab498/6382154
- 18. Egwang TG, Owalla TJ, Okurut E, Apungia G, Fox A, De Carlo C, et al. Differential pre-pandemic
 breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in
 Ugandan and American mothers. Int J Infect Dis 2021: S1201-9712(21)00747-5.
 doi:10.1016/j.ijid.2021.09.039
- 19. Hassan MM, Sharmin S, Hong J, Lee HS, Kim HJ, Hong ST. T cell epitopes of SARS-CoV-2 spike
 protein and conserved surface protein of *Plasmodium malariae* share sequence homology.
 Open Life Sci. 2021; 16:630-640. doi:10.1515/biol-2021-0062
- 20. Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas C, et al. *Plasmodium* infection
 induces cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein.
 medRxiv [Preprint]. 2021 May 12; doi:10.1101/2021.05.10.21256855
- 294 21. Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and
 295 pseudovirus neutralizing antibody titers after infection, compared by HIV status: a matched
 296 case-control observational study. Lancet HIV 2021. DOI: 10.1016/S2352-3018(21)00072-2.
- 22. Snyman J, Hwa SH, Krause R, Muema D, Reddy T, Ganga Y, et al. Similar antibody responses
 against SARS-CoV-2 in HIV-uninfected and infected individuals on antiretroviral therapy
 during the first South African infection wave. Clin Infect Dis 2021; Sep 2 [Epub ahead of print].
 doi:10.1093/cid/ciab758
- 301 23. Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, Díez C, Micán R, Pérez-Elías MJ, et al.
 302 Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV
 303 individuals after COVID-19. J Infect 2021; 84:418-467. doi: 10.1016/j.jinf.2021.11.002

- 304 24. Wolday D, Ndungu FM, Gómez-Pérez GP, Rinke de Wit TF. Chronic immune activation and
- CD4+ T cell lymphopenia in healthy African individuals: Perspectives for SARS-CoV-2 vaccine
 efficacy. Front Immunology 2021; 12: 693269.
- 307 25. Kilian HD, Nielsen G. Cell-mediated and humoral immune response to tetanus vaccinations in
 308 onchocerciasis patients. Trop Med Parasitol 1989; 40:285–291.
- 309 26. Harris JB, Podolsky MJ, Bhuiyan TR, Chowdhury F, Khan AI, Larocque RC, Logvinenko T, et al.
- Immunologic responses to *Vibrio cholerae* in patients co-infected with intestinal parasites in
 Bangladesh. *PLoS Negl Trop Dis* 2009; 3:e403. doi:10.1371/journal.pntd.0000403
- 27. Esen M, Mordmüller B, de Salazar PM, Adegnika AA, Agnandji ST, Schaumburg F, Hounkpatin
- AB, et al. Reduced antibody responses against *Plasmodium falciparum* vaccine candidate
- antigens in the presence of *Trichuris trichiura*. *Vaccine* 2012; 30:7621–7624.
 doi:10.1016/j.vaccine.2012.10.026
- 28. Nono JK, Kamdem SD, Netongo PM, Dabee S, Schomaker M, Oumarou A, et al.
 Schistosomiasis Burden and Its Association With Lower Measles Vaccine Responses in School
 Children From Rural Cameroon. Front Immunol 2018; 9:2295.

doi:10.3389/fimmu.2018.02295

- 29. Riner DK, Ndombi EM, Carter JM, et al. *Schistosoma mansoni* infection can jeopardize the
 duration of protective levels of antibody responses to immunizations against hepatitis B and
 tetanus toxoid. PLoS Negl Trop Dis 2016; 10:e0005180.
- 30. Apiwattanakul N, Thomas PG, Iverson AR, McCullers JA. Chronic helminth infections impair
 pneumococcal vaccine responses. Vaccine 2014; 32:5405–5410.
 doi:10.1016/j.vaccine.2014.07.107
- 31. Hartmann W, Brunn ML, Stetter N, Gagliani N, Muscate F, Stanelle-Bertram S, et al. Helminth
 infections suppress the efficacy of vaccination against seasonal influenza. Cell Reports 2019;
 29:2243-2256. doi:10.1016/j.celrep.2019.10.051
- 329 32. Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et al.
 Clinical features and risk factors associated with morbidity and mortality among COVID-19
 patients in Northern Ethiopia. Int J Infect Dis 2021; 105: 776-783.

332 33. International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). COVID 333 19 CRF. https://isaric.tghn.org/COVID-19- CRF/. (Accessed Aug 28, 2020).

- 334 34. Gebrecherkos T, Kiros YK, Challa F, Abdella S, Gebreegzabher A, Leta D, et al. Longitudinal 335 profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub–
- 336 Saharan Africa: A prospective longitudinal study. PLoS One 2022; 17:e0263627.
- doi:10.1371/journal.pone.0263627
- 338 35. Wolday D. Gebrecherkos T, Arefaine ZG, Kiros YK, Gebreegzabheer A, Tasew G, et al. Effect of
- co-infection with parasites on COVID-19 severity: A prospective cohort study.
 eClinicalMedicine 2021; 39: 101054. doi:10.1016/j.eclinm.2021.101054
- 36. Adjobimey T, Meyer J, Terkeš V, Parcina M, Hoerauf A. Helminth antigens differentially
 modulate the activation of CD4⁺ and CD8⁺ T lymphocytes of convalescent COVID-19 patients
- 343 in vitro. BMC Med 2022;20: 241-252. doi:10.1186/s12916-022-02441-x
- 37. Egwang TG, Owalla TJ, Kemigisha M. COVID-19 vaccine trials must include helminth-infected
 cohorts. Nat Immunol 2022; 23:148. doi: 10.1038/s41590-021-01116-8
- 346

 347

 348

 349

 350

 351

 352

 353

 354

 355

 356

 357

 358

 359

 360

361 Table 1: Clinical features among COVID-19 patients without, or with parasite co-infection

Characteristic	All patients N=74	Without parasite N= 35 (47.3)	With parasite N=39 (52.7)	p-value
Socio-demographic features:				
Male sex	57 (77.0)	26 (75.3)	31 (79.5)	0.595
Age in years (median, IQR)	35 (28-50)	37 (28-55)	34 (28-43)	0.368
Clinical symptoms:				
Fever	23 (31.1)	12 (34.3)	11 (28.2)	0.573
Dyspnea	30 (40.5)	19 (54.3)	11 (28.2)	0.023
Cough	34 (46.0)	19 (54.3)	15 (38.5)	0.173
Chest pain	7 (9.5)	3 (8.6)	4 (10.3)	0.805
Sore throat	5 (6.8)	3 (8.6)	2 (5.1)	0.556
Headache	21 (28.4)	13 (37.1)	8 (20.5)	0.113
Nasal congestion	5 (6.8)	1 (2.9)	4 (10.3)	0.205
Loss of smell and/or taste	3 (4.1)	1 (2.9)	2 (5.1)	0.621
Nausea/vomiting	5 (6.8)	3 (8.6)	2 (5.1)	0.556
Myalgia	8 (10.8)	4 (11.4)	4 (10.3)	0.871
Comorbidities				
Comorbidity (at least 1)	21 (28.4)	10 (28.6)	11 (28.2)	0.972
Non–communicable diseases (NCDs)	18 (24.3)	8 (22.9)	10 (25.6)	0.780
Outcomes				
Severe COVID–19	29 (39.2)	17 (48.6)	12 (30.8)	0.117
Parasite co-infection	39 (52.7)	-		-
Protozoa - any	26 (35.1)	-		-
Entamoeba spp. cyst	18 (24.3)	-		-
Entamoeba histolytica trophozoite	5 (6.8)	-		-
Giardia lamblia trophozoite	3 (4.1)	-		-
Helminth – any	19 (25.7)	-		-
Hymenolopis nana	15 (20.3)	-		-
Schistosoma mansoni	2 (2.7)	-		-
Ascaris lumbricoides	3 (4.1)	-		-
Poly–parasitism – any	9 (12.2)	-		-

362 *Data are presented as proportion (%) unless indicated

Helminth Parasite Protozoa Anti-NP total Ig* Positive Negative Positive P-value Negative P-value Negative Positive P-value 174/261 231/328 290/424 115/165 0.760 254/377 151/212 0.333 Positivity rate 0.328 (66.7) (70.4) (69.7) (67.4) (71.2) (68.4) Anti-NP total Ig titer 7.51 6.91 0.764 6.84 7.49 0.676 7.51 6.79 0.737 (COI) (0.21-59.21) (0.55-40.70) (0.58-42.35) (0.23-50.57)(0.62-39.86) (0.28-48.99) Data presented as numbers and percentage positivity rate, or median (IQR) cut-off index (COI). The COI for positive anti-NP total Ig is \geq 1.0. 365 366 367 368 369 370 371 372 373 374 375 376

364 Ta	able 2. Profile of anti-SARS-CoV-2 NP total Ig res	ponse among COVID-19 patients with	or without intestinal parasite co-infection

381 Figure legends:





Figure 1. Anti-NP total Ig positivity rate (A-C) and titer levels (D-F) at different time points after onset of symptoms stratified by the parasite (A, D), helminth (B, E) and protozoa (C, F) co-infection status. The red dashed horizontal line (D-F) represents the cut-off value of the limit of detection of the anti-NP total Ig assay.

386

387



388

Figure 2. Seroconversion rate (A) and titers levels (B) of anti-NP total Ig at different time points after onset of symptoms stratified by parasite co-infection status. The red dashed horizontal line (B) represents the cut-off value of the limit of detection of the anti-NP total Ig assay.